{
    "eid": "2-s2.0-85109190174",
    "title": "How to Sequence Therapies in Peripheral T Cell Lymphoma",
    "cover-date": "2021-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Autologous stem cell transplantation",
        "Chemotherapy",
        "Lymphoproliferative disorder",
        "T cell lymphoma"
    ],
    "authors": [
        "Kitsada Wudhikarn",
        "N. Nora Bennani"
    ],
    "citedby-count": 3,
    "ref-count": 90,
    "ref-list": [
        "2016 US lymphoid malignancy statistics by World Health Organization subtypes",
        "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001",
        "Non-Hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features, and survival from Thailand",
        "International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes",
        "Peripheral T cell lymphoma in Asia",
        "The 2016 revision of the World Health Organization classification of lymphoid neoplasms",
        "Peripheral T-cell lymphoma",
        "Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study",
        "Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma",
        "Comparison of four prognostic scores in peripheral T-cell lymphoma",
        "Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas",
        "A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma",
        "Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350",
        "CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial",
        "A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial",
        "A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 studydagger",
        "Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial",
        "Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group",
        "Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in previously untreated patients with peripheral t-cell lymphoma (PTCL): a phase 1 dose-escalation study",
        "Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma",
        "Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma",
        "Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma",
        "Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma",
        "Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study",
        "Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study",
        "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial",
        "An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of Consolidative Stem Cell Transplant",
        "Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK)",
        "Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: the result of the nationwide multi-institutional registry Thai Lymphoma Study Group",
        "Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma",
        "Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: a review of 124 patients",
        "Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma",
        "Post-therapy (1)(8)F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma",
        "Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients",
        "Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01",
        "Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study",
        "Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma",
        "The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience",
        "ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes",
        "DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study",
        "The impact of upfront autologous transplant on the survival of adult patients with ALCL and PTCL-NOS according to their ALK, DUSP22 and TP63 gene rearrangement status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis",
        "Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma",
        "Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center",
        "Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma",
        "Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis",
        "Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation",
        "Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry",
        "Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors",
        "The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project",
        "Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry",
        "Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study",
        "Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy",
        "Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study",
        "Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin",
        "Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial",
        "Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma",
        "Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas",
        "Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas",
        "Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma",
        "Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial",
        "Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine",
        "Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review",
        "Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: a French retrospective multicenter study",
        "Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas",
        "The Bbv regimen: a phase II study with bendamustine plus brentuximab vedotin in Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma in first salvage setting",
        "Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial",
        "Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy",
        "Safety and efficacy of crizotinib in ALK-positive lymphomas: a phase 1b open-label study",
        "Proof of concept for tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL): preliminary results from an open-label, phase 2 study",
        "Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral t cell lymphoma (PTCL)",
        "The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma",
        "Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen",
        "Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire",
        "Successful treatment of peripheral T-cell lymphoma with allogeneic stem cell transplantation: a large single-center experience",
        "Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis",
        "A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome",
        "Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma",
        "GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features",
        "Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry",
        "The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells",
        "RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis",
        "A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma",
        "Somatic RHOA mutation in angioimmunoblastic T cell lymphoma",
        "Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma",
        "Rapid and durable complete remission of refractory AITL with azacitidine treatment in absence of TET2 mutation or concurrent MDS",
        "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study",
        "T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma",
        "STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma",
        "STAT3 mutation is associated with STAT3 activation in CD30(+) ALK(-) ALCL",
        "Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Rochester",
            "@id": "60005558",
            "affilname": "Mayo Clinic",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005558",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Thai Red Cross Society",
        "King Chulalongkorn Memorial Hospital"
    ]
}